ArticleBMC ophthalmology2025
Association between stress hyperglycemia ratio and neovascular glaucoma in patients with proliferative diabetic retinopathy.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neovascular glaucoma: pathophysiology, diagnosis, and contemporary management.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to investigate the association between the stress hyperglycemia ratio (SHR) and the occurrence of neovascular glaucoma (NVG) in patients with proliferative diabetic retinopathy (PDR). We aimed to explore the potential role of SHR as a biomarker for NVG risk and to identify demographic and clinical modifiers of this association.
methodsWe conducted a retrospective cohort study using electronic health records from our hospital over a 10-year period from 2010 to 2020. Patients diagnosed with PDR were included, with exclusions for those without diabetes-related NVG or incomplete SHR data. The SHR was calculated using admission blood glucose and HbA1c levels. Logistic regression and Cox proportional hazards modeling were used to assess the association between SHR and NVG, adjusting for potential confounders.
resultsA total of 1,245 patients were identified, of which 378 (30.3%) had PDR with NVG. The mean SHR for the entire cohort was 2.9, with a higher mean SHR observed in the PDR with NVG group (3.2 vs. 2.7, p < 0.001). Multivariate logistic regression analysis revealed a significant association between SHR and NVG (OR 2.5, 95% CI 1.9 to 3.3, p < 0.001). Subgroup analysis showed a stronger association between SHR and NVG risk in males (HR 1.4, 95% CI 1.1 to 1.7, p = 0.01) and patients over 65 years old (HR 1.5, 95% CI 1.2 to 1.9, p = 0.001). The association was also more pronounced in patients with a diabetes duration exceeding 15 years (HR 1.4, 95% CI 1.1 to 1.8, p = 0.01).
conclusionOur study demonstrated a significant association between SHR and NVG with PDR patients, with certain subgroups showing a stronger association. These findings suggest that glycemic variability, as measured by SHR, may play a critical role in the development of NVG and could inform tailored clinical strategies for the prevention and management of NVG in high-risk patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.